Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 15, 2024

Samsung Biologics launches biopharmaceutical platform S-HiCon

Samsung Biologics, a contract development and manufacturing organisation (CDMO), has launched S-HiCon, a new high-concentration formulation platform designed to enhance the development and manufacturing of high-dose drugs.

Continue
The platform aims to proactively recognise unintended pH changes, bolster formulation stability, and reduce viscosity to ensure efficacy and optimise drug delivery. Credit: Diane Serik on Unsplash.
October 14, 2024

Stealth’s elamipretide gains FDA advisory committee support for Barth syndrome

The committee's decision was informed by data from the TAZPOWER Part II baseline-controlled extension study. Credit: National Cancer Institute on Unsplash.
October 10, 2024

insitro collaborates with Lilly on metabolic disease treatments

The partnership will combine insitro’s machine learning platforms with capabilities of Lilly in drug delivery and metabolic disease biology. Credit: Michal Jarmoluk from Pixabay.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Volixibat gains FDA breakthrough therapy designation
  2. PsychoGenics secures NIH contract to identify new pain therapeutics
  3. Neuvivo files NDA seeking FDA approval for ALS treatment
  4. AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy
  5. FDA grants priority review for AstraZeneca’s Calquence sNDA

PRESS RELEASES

Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer Remains on Track in First Half of 2024
Gerresheimer Remains on Track in First Half of 2024
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation